المؤلفون: Joanne Chiu, Thomas Yau, Chung Mau Lo, Bryan Cho Wing Li, Jeffrey Sum Lung Wong, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Vikki Tang, Roland Leung, Wong Hoi She

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Time Factors, medicine.medical_treatment, Pembrolizumab, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Tumor Microenvironment, Immunology and Allergy, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, Clinical/Translational Cancer Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, drug therapy, Nivolumab, Treatment Outcome, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Disease Progression, Molecular Medicine, Female, immunotherapy, medicine.drug, CTLA-4 antigen, medicine.medical_specialty, Carcinoma, Hepatocellular, Immunology, Ipilimumab, Antibodies, Monoclonal, Humanized, programmed cell death 1 receptor, 03 medical and health sciences, Refractory, Internal medicine, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Salvage Therapy, combination, Pharmacology, liver neoplasms, business.industry, Immunotherapy, medicine.disease, 030104 developmental biology, Drug Resistance, Neoplasm, Tumor progression, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627bcbe652eea3c3d5d4c78657177083
https://doi.org/10.1136/jitc-2020-001945